Basic Information
ID: ALA3888224
Type: Binding
Description: Discontinuous Radiometric Assay: Compounds may be evaluated as selective reversible inhibitors of AKR1C3 by screening them against homogeneous recombinant AKR1C1-AKR1C4 expressed in E. coli. In each case, a discontinuous radiometric assay may be used to monitor the inhibition of progesterone reduction (20-ketosteroid reduction) catalyzed by AKR1C1, the inhibition of Δ4-AD reduction (17-ketosteroid reduction) catalyzed by AKR1C3, and the inhibition of 5α-DHT reduction (3-ketosteroid reduction) catalyzed by AKR1C2 and AKR1C4 (by measuring the formation of 20α-hydroxyprogesterone, testosterone or 3α-androstanediol by radiochromatography). Secondary screens of the compounds of interest include: (a) a full-screen against all nine human recombinant AKR enzymes to ensure there are no-intended off-target effects (in this context AKR1B10 (retinal reductase; SEQ ID NO:5) has been shown to be potently inhibited by N-phenylanthranilates) (Endo et al., 2010, Biol. Pharm. Bull. 33:886-90); (b) a screen against COX-1 and COX-2 to reaffirm that compounds do not act as NSAIDs; and (c) an expanded screen against other nuclear receptors (especially other steroid hormone receptors).
Organism: Homo sapiens
Activity Charts
Bioactivity
Activity Types for Assay ALA3888224
Ki
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 357.79 | 3.93 | 3.93 |
| 284.75 | 3.15 | 3.15 |
| 281.23 | 4.15 | 4.15 |
| 213.24 | 3.13 | 3.13 |
| 386.53 | 4.66 | 4.66 |
| 238.24 | 3.17 | 3.17 |
| 210.27 | 2.41 | 2.41 |
| 213.24 | 3.13 | 3.13 |
| 213.24 | 3.13 | 3.13 |
| 258.23 | 3.04 | 3.04 |
| 255.27 | 3.33 | 3.33 |
| 281.23 | 4.15 | 4.15 |
| 247.68 | 3.78 | 3.78 |
| 292.13 | 3.89 | 3.89 |
| 269.34 | 4.43 | 4.43 |
| 243.26 | 3.14 | 3.14 |
| 227.26 | 3.44 | 3.44 |
| 349.22 | 3.48 | 3.48 |
| 356.81 | 3.63 | 3.63 |
| 326.23 | 4.06 | 4.06 |
| 288.26 | 3.05 | 3.05 |
| 322.32 | 4.28 | 4.28 |
| 303.23 | 2.94 | 2.94 |
| 299.28 | 3.03 | 3.03 |